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Abstract
Activating mutations of Kras oncogene and deletions of Pten tumor suppressor gene play important roles in cancers of the
female genital tract. We developed here new preclinical models for gynecologic cancers, using conditional (Cre-loxP) mice
with floxed genetic alterations in Kras and Pten. The triple transgenic mice, briefly called MUC1KrasPten, express human
MUC1 antigen as self and carry a silent oncogenic KrasG12D and Pten deletion mutation. Injection of Cre-encoding
adenovirus (AdCre) in the ovarian bursa, oviduct or uterus activates the floxed mutations and initiates ovarian, oviductal,
and endometrial cancer, respectively. Anatomical site-specific Cre-loxP recombination throughout the genital tract of
MUC1KrasPten mice leads to MUC1 positive genital tract tumors, and the development of these tumors is influenced by the
anatomical environment. Endometrioid histology was consistently displayed in all tumors of the murine genital tract
(ovaries, oviducts, and uterus). Tumors showed increased expression of MUC1 glycoprotein and triggered de novo
antibodies in tumor bearing hosts, mimicking the immunobiology seen in patients. In contrast to the ovarian and
endometrial tumors, oviductal tumors showed higher nuclear grade. Survival for oviduct tumors was significantly lower
than for endometrial tumors (p = 0.0015), yet similar to survival for ovarian cancer. Oviducts seem to favor the development
of high grade tumors, providing preclinical evidence in support of the postulated role of fallopian tubes as the originating
site for high grade human ovarian tumors.
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Introduction
The American Cancer Society estimates over 91,000 new cases
and 28,000 deaths due to gynecological cancers in 2013 [1].
Taken together, ovarian and endometrial tumors constitute about
78% of all female genital tract tumors. The most common
gynecologic malignancy is endometrial cancer, which is often
detected early and can be successfully treated with surgery and/or
radiotherapy. In contrast, epithelial cancer of the ovary is
relatively uncommon yet highly aggressive, accounting for most
of the mortality. Primary fallopian tube cancers (without ovarian
involvement) are also rare, accounting for 0.2% of cancer cases
diagnosed annually [2] and, like ovarian tumors, are detected late
and have a poor prognosis [3].
Traditionally, epithelial ovarian tumors have been thought to
develop from the ovarian surface epithelium into four major
histotypes: serous, endometrioid, mucinous and clear cell. It is now
apparent that ovarian tumors are highly heterogeneous and may
represent several different clinical entities, with distinct clinical
precursors. High grade serous tumors carry p53 mutations and are
considered to arise mostly in the fallopian tubes [4,5]. Although
this type of tumor has been fully characterized through The
Cancer Genome Atlas (TCGA) [6], similarly comprehensive
analyses of the other ovarian cancer subtypes are not yet available
[7–9]. Nevertheless, based on substantial evidence from several
studies, it is currently accepted that, at least in part, the
endometrioid and clear cell ovarian tumor histotypes share
endometriosis as a putative common precursor [10] and display
frequent inactivating mutations in ARID1A [7,11].
Low grade (type I) endometrial and ovarian cancers, as well as
tubal intraepithelial carcinomas are frequently associated with
oncogenic KRASG12D and PTEN deletion mutations [3,12] or
altered expression [13]. The recent TCGA study of 373
endometrial tumors identified the KRAS and PTEN genes as
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being mutated in 24.6% and 77% of endometrioid tumors
respectively, emphasizing the influence of these mutations in
gynecologic cancer pathogenesis [14].
Involvement of the KRAS and PTEN pathways has led to the
development of several genetically modified preclinical models for
type I gynecological cancers [15–20]. Using conditionally trans-
genic mice carrying both oncogenic KrasG12D and a floxed Pten
deletion, Dinulescu et al demonstrated the importance of these two
pathways in triggering ovarian tumors with endometrioid histology
[21]. Mice defective in Pten have also been reported as valuable
preclinical models for endometrioid endometrial tumors [22].
However, in vivo modeling of oviduct tumors (the murine
equivalent of fallopian tube tumors) has proven more challenging
with only few orthotopic models reported to date [15,23].
While some of the mouse models for gynecologic malignancies
have been helpful in delineating mechanisms of pathogenesis
[21,24,25], they offer limited utility for immunotherapy due to the
absence of well characterized mouse tumor antigens. To overcome
this, we generated triple transgenic MUC1+/2loxP-STOP-loxP-
KrasG12D/+PtenloxP/loxP (or briefly MUC1KrasPten) mice that, at
steady state, express physiologic levels of human mucin 1 (MUC1)
as self-antigen [26]. MUC1 is a membrane-bound glycoprotein
that is overexpressed and aberrantly glycosylated in most epithelial
cell-derived cancers, including genital tract tumors [27]. MUC1-
targeted immunotherapy is under development for several cancers
and has been administered so far to about 1200 patients, while
more than 2000 patients are currently enrolled in ongoing clinical
trials [28]. Using the MUC1KrasPten mouse model, we have
recently demonstrated that intrabursal injections of AdCre (to
activate oncogenic Kras and induce Pten loss in the ovaries)
[21,26] trigger endometrioid ovarian tumors. The tumors
overexpress human MUC1 similarly to the human disease and
respond to MUC1 immunotherapy, further strengthening the
evidence on its efficacy as a target in ovarian cancer [26].
Here, we show how conditional mutations in Kras and Pten
genes can be manipulated throughout the genital tract of double
(KrasPten) and triple transgenic (MUC1KrasPten) mice, using
injections of Cre-encoding adenovirus (AdCre) in the ovarian
bursa, oviduct or uterine horns. Although all tumors, regardless of
the originating site, display endometrioid histology, oviducts seem
to favor the development of high grade tumors, providing
preclinical evidence in support of the postulated role of fallopian
tubes as the originating site for high grade, human ovarian tumors.
Materials and Methods
Survival surgery and administration of recombinant
adenovirus for tumor induction
All animal experiments were performed according to the
protocol approved by the University of Pittsburgh Institutional
Animal Care and Use Committee. Figure 1 shows the gross
anatomy of the murine female genital tract from a healthy mouse,
as well as a diagram of the ovarian bursa, oviduct and uterine sites
of AdCre injection approach.
Briefly, 7–10 weeks old female mice were synchronized by intra-
peritoneal (IP) injection of 5 U of pregnant mare serum
gonadotropin (PMSG, Sigma, St. Louis, MO), followed 48 hours
later by 5 U of human chorionic gonadotropin (hCG, Calbio-
chem, Billerica, MA) as previously described [21]. Thirty six hours
later, 5 ml of 2.56107 plaque-forming units of Ad5CMVCre
(University of Iowa Gene Transfer Vector Core) were delivered
into either the ovarian bursa of the left ovary (n = 12), or the left
oviduct (n = 9) or the left uterine horn (n= 12). The contra lateral
(right) ovary/oviduct/uterine horn was used as control. A subset of
oviduct injections (n = 4) were performed after clipping the oviduct
at the proximal and distal ends using the GEM MicroClips
(Synovis Life Technologies, Birmingham, AL) to ensure retention
of the adenovirus within the oviduct.
The mice were sacrificed when the tumor mass on the injected
side and/or ascites accumulation became visible or the mice
showed signs of distress that were pre-defined as endpoints (i.e.
hunched appearance, ruffled fur, difficulty in reaching for food or
water etc).
Administration of AdLacZ adenovirus and staining for
LacZ expression
Ovulation was synchronized as above in control female mice.
Five microliters of 2.56107 plaque-forming units of the AdLacZ
adenovirus (University of Iowa Gene Transfer Vector Core) were
then delivered into proximally and distally clipped oviducts (n = 2)
or the uterus (n = 2). Mice were sacrificed 3–7 days post virus
administration and the tissues fixed and stained for LacZ
expression using the LacZ Detection Kit for Tissues, according
to the manufacturer’s instructions (Invivogen, San Diego, CA).
After staining, the tissues were embedded in paraffin and blocks
were sectioned at 5 mm, followed by H&E staining to visualize the
histology of the AdLacZ infected sites.
Tissue isolation, histopathology and
immunohistochemistry
Mouse internal organs (reproductive tract, spleen, peritoneal
tumor masses and diaphragm), blood and ascites were collected
during necropsy. Harvested tissue was fixed in 10% buffered
formalin (Fisher Scientific, Kalamazoo, MI) for 24 hours, stored in
70% ethanol for 3 days and subsequently embedded in paraffin.
Five micron sections were cut and the gross histopathology was
assessed by H&E staining. For immunohistochemistry (IHC), the
slides were blocked using 3% hydrogen peroxide in methanol and
antigen retrieval was performed by boiling the slides for 20
minutes in citrate buffer, pH 6. The following antibodies were
used for IHC: anti-human MUC-1 (HMPV, 1:100, BD Pharmin-
gen, San Diego, CA), cytokeratin 8 (B0017, 1:50, Assay Biotech,
Sunnyvale, CA), and desmin (sc7559, 1:50, Santa Cruz Biotech-
nology, Dallas, TX). Secondary antibodies used include anti-
rabbit-HRP (K4003, Dako, Carpinteria, CA) for cytokeratin 8,
and anti-goat-HRP for desmin (sc2020, 1:50, Santa Cruz
Biotechnology, Dallas, TX). Biotinylated anti-mouse IgG
(550337, 1:100; BD Pharmingen, San Jose, CA) was used as the
secondary antibody for anti-MUC1, followed by the VectaStain
ABC Kit (Vector Laboratories, Burlingame, CA). The positive
signal was detected using the DAB chromogen (DAB Substrate
Kit, Abcam, Cambridge, MA) and the slides were counterstained
using hematoxylin. To ensure specificity of staining, control
sections were stained with either isotype control antibodies or no
primary antibody.
Human serous tubal intraepithelial carcinoma (n= 1), human
endometrioid endometrial carcinoma (n= 4) and human endo-
metrial hyperplasia (n = 3) were obtained as per IRB guidelines
from the Health Science Tissue Bank of the Magee Women’s
Hospital, Pittsburgh. The protocols for processing and IHC
staining of human tumors were similar to those described above,
for mouse tumors.
Image processing and analysis
Images were acquired with the Nikon Eclipse 90i microscope
and Nikon DS-Ri1 CCD camera, using NIS Elements AR
software or the Nikon Eclipse 600 microscope with the DS-L3
Novel Mouse Models for MUC1+ Genital Tract Tumors
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CCD camera. Images acquired were processed with Adobe
Photoshop CS5.
DNA isolation and PCR analysis of Cre-mediated
recombination
DNA was isolated from 5 mm tissue sections of primary tumors
using All Prep RNA/DNA/Protein isolation kit as per the
manufacturer’s instructions (Qiagen, Valencia, CA). Tails from
non-tumor bearing, healthy control mice were snap-frozen after
collection and DNA was later isolated using Puregene DNA
purification system (Gentra Systems, Minneapolis, MN), according
to manufacturer’s instructions. The primers and complete PCR
protocols to detect K-rasG12D and Pten deletion mutations have
been described previously [26].
Flow cytometry
Spleens were collected at necropsy and a single cell suspension
was obtained by passing the tissue fragments through a 70 mm cell
strainer (BD Falcon, Franklin Lake, NJ, USA). Cells were stained
with fluorescent antibodies for CD3 (PerCP), CD4 (Pacific Blue),
and CD8 (APC-Cy7) (all antibodies from BD Biosciences, San
Jose, CA), followed by intracellular staining for Foxp3
(eBioscience, San Diego, CA), according to the manufacturers’
protocols.
To detect anti-MUC1 antibodies, samples were incubated with
IG10-MUC1 cells [29] expressing extracellular human MUC1.
To detect bound antibodies, the cells were then stained with
fluorescein tagged anti-mouse IgG and positive cells analyzed with
LSRII (BD Biosciences) and processed in FACSDiva (BD
Biosciences). Gates for positive cells were set using control ascites,
from tumor bearing KrasPten (i.e. human MUC1 negative) mice.
ELISA
To detect MUC1-specific antibodies in sera from MUC1K-
rasPten mice with tumors (n = 5 ovarian, n= 4 oviductal and n= 4
uterine tumors) we performed ELISA, as previously described by
us and others [29]. Briefly, ELISA plates were coated with 10 mg/
Figure 1. Induction of floxed KrasG12D and Pten mutations in the female genital tract results in large tumors at the primary site,
accompanied at late stages by numerous peritoneal implants. (A) Left panel: female genital tract anatomy of a healthy mouse (Ov, ovaries;
OvB, ovarian bursa; OvD, oviduct; UT, uterus). Right panel: schematic representation of the murine female genital tract showing the ovaries, oviducts
and uterine horns. Arrows indicate AdCre delivery routes: under the ovarian bursa, inside the oviduct and inside the uterine horn. All injections were
unilateral, keeping the contralateral site as control. (B) Mice carrying conditional mutations in oncogenic KrasG12D and tumor suppressor Pten
pathways were injected with AdCre either under the left ovarian bursa (n = 12), left oviduct (n = 9), or left uterine horn (n = 12). Representative gross
images of primary tumors (left column) are shown for ovarian, oviductal and uterine injections. Right column shows numerous loco- regional
metastatic small tumor deposits (arrows) that accompany the corresponding primary tumor. The nodules were often located on the diaphragm
(upper and lower panels) and liver (middle panel).
doi:10.1371/journal.pone.0102409.g001
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ml 100mer MUC1 peptide comprising five 20 amino-acid long
tandem repeats from the MUC1 extracellular domain. Similarly
diluted sera from two mice with MUC1 negative (wild type)
tumors, as well as dilution medium alone were chosen as negative
controls. Samples were run in duplicate for each of the two
dilutions (1:20 and 1:40, respectively). Horseradish peroxidase
(HRP) –conjugated secondary antibody specific for mouse IgG
(Sigma, 1:500) was used for detection. Median and standard errors
were plotted in Excel.
Survival curve and statistical analysis
The Kaplan-Meyer survival curve was plotted using the
GraphPad Prism 6 software. The same software, as well as Excel
were used to perform ANOVA or Student’s t test and to compute
p values for statistical significance.
Results
Induction of oncogenic KrasG12D and deletion of Pten in
the oviduct or the uterine horns triggers progression to
ductal and endometrial tumors, respectively
To explore the tumorigenic contributions of oncogenic Kras
and tumor suppressor Pten pathways throughout the female
genital tract of genetically engineered, Cre-loxP mice [21,26], we
injected AdCre adenovirus at three different anatomical locations
(Fig. 1A). The mice received one, unilateral AdCre injection either
in the ovarian bursa (n = 12), oviduct (the fallopian tube
equivalent, n = 9) or uterine horn (n= 12). Activation of Kras
and deletion of Pten transformed the oviductal and endometrial
tissues, resulting in establishment of primary tumors at these sites
(Fig. 1B). Oviductal tumors showed 100% tumor penetrance
(n = 9), similarly to ovarian tumors [21,26]. Tumor penetrance
was lower (at 50%) following intrauterine (IU) AdCre injections.
Intrabursal injections triggered primary ovarian tumors as shown
previously [21,26] and were used as reference standard (Fig. 1B).
Gross loco-regional metastases were often observed in late stage
tumors of oviduct and uterus (Fig. 1B) and were detected as tumor
implants on the diaphragm, liver, and spleen. Only one of the 12
uterine-injected mice presented with ascites (8%) while 5 out of 9
oviduct injected mice showed ascites (56%, p= 0.0163). Ascites,
when detected, was of the hemorrhagic type. No tumors were
detected in the ovaries, oviduct and uterine-AdCre injected mice
carrying mutations in either Kras alone (MK mice) or Pten alone
(MP mice, data not shown), suggesting that, as with ovarian
tumors [26], both pathways need to be active in order for tumors
to occur. AdCre was also injected in MUC1 single transgenic mice
(included as controls) which, as expected, remained healthy
throughout the duration of the experiment. This demonstrates
that in the absence of floxed mutations in the host genome,
adenoviral infection is non-consequential for the host.
DNA of all primary tumors was analyzed by PCR to confirm
the activation of the floxed sites in Kras and Pten genes [26]. As
expected, the oviductal and uterine tumors showed the presence of
both the active KrasG12D and the wild type Kras alleles, along with
homozygous deletion of Pten (Fig. S1A–C). Normalization results
of mutant (floxed) Kras to wild type Kras from tumors are in line
with the expected 1:1 ratio (50% mutant Kras), although the
oviduct and endometrial show slightly lower and higher ratios,
respectively (Fig. S1D). A similar efficiency of recombination was
observed for floxed Pten that could be detected in these lesions
(Fig. S1E). In contrast, no wild type was detected, consistent with
the fact that macro-dissected tissue consisted mostly of epithelium.
However, a weak band for wild type Pten could be detected in the
ex vivo isolated ovarian tumor cell line using freshly isolated DNA,
Figure 2. Primary tumors of the ovary, oviduct and uterus have epithelial origin. Immunohistochemistry staining of tumors occurring in
the ovary (upper panels), oviduct (middle panels) or endometrium (lower panels). Antibodies to mouse cytokeratin 8 (an epithelial cell marker, left
column) and mouse desmin (right column) were used at 1:50 dilution. Representative images shown. Scale bar 250 mm.
doi:10.1371/journal.pone.0102409.g002
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also suggesting the negative result can in part be due to a limitation
in detecting residual Pten by PCR when using paraffin-extracted
DNA (Fig. S1F). Through reporter gene (AdLacZ) experiments,
we further confirmed that injections remain anatomically confined
and effectively trigger local epithelial infection of uterus, oviduct
and ovaries (Fig. S2).
Oviductal and uterine tumors are of epithelial origin and
show endometrioid histology
Both oviductal and uterine tumor cells were positive for
cytokeratin 8, an epithelial marker, and negative for desmin, a
stromal cell marker (Fig. 2), confirming the epithelial origin of
these tumors. Similarly to KrasPten- induced ovarian tumors
obtained via AdCre injections under the ovarian bursa [21], both
the oviductal and uterine primary tumors displayed endometrioid
histology (Fig. 3). The endometrioid histology was also preserved
in loco-regionally spread tumor implants (Fig. 3). Our findings
demonstrate that, in this preclinical model, co-involvement of Kras
and Pten tumorigenic pathways throughout the genital tract
(ovaries, oviduct and uterus) consistently triggers gynecologic
tumors with endometrioid histology. Notably however, some of the
uterine lesions in mice sacrificed early, potentially before tumor
onset, showed glandular hyperplasia with cystic dilation (Fig. S3).
KrasPten-driven oviductal and uterine tumors express
human MUC1 and trigger spontaneous anti-MUC1
antibodies
We have previously shown that triple transgenic MUC1KrasP-
ten mice, injected with AdCre under the ovarian bursa, develop
human MUC1-expressing ovarian tumors, closely mirroring the
human disease [21,26]. In this study, we examined whether the
oviductal and uterine tumors also expressed MUC1 upon Kras
activation and Pten deletion in MUC1KrasPten mice. Our IHC
results demonstrate that the tumors lost polarized MUC1
expression normally seen on healthy epithelia (Fig. S4), and show
abundant cell surface and cytosolic MUC1 (Fig. 4), similar to the
staining pattern observed in human tumors (Fig. S5 and references
[30,31]).
In patients, MUC1 overexpression on developing adenocarci-
nomas leads to spontaneous humoral responses to various MUC1
epitopes from its extracellular domain [32,33]. We asked here
whether the gynecologic tumors in MUC1KrasPten mice that
express MUC1 antigen as self also trigger MUC1-specific humoral
immunity. ELISA measurements show that although the ampli-
tude of the response varies, presence of MUC1-specific IgG
antibodies can be detected in serum of tumor bearing mice
(Fig. 4B) and the levels are significantly higher in mice with
ovarian and oviduct tumors. Since the target peptide is a 100mer
MUC1 peptide comprising five tandem repeats from the
Figure 3. Oviductal and endometrial tumors show endometrioid histology at both primary and satellite locations. Formalin fixed and
paraffin embedded primary and metastatic tumor tissues were analyzed for histo-pathology. Representative images of H&E stained tumor sections
are shown. Left column: primary tumors of the genital tract show endometrioid histology in the ovary, oviduct and endometrium. Right column:
secondary tumors, including ovarian metastases to the diaphragm (upper), oviduct metastases to the pancreas (middle) and endometrial metastases
to the diaphragm (lower) also show endometrioid histology. Scale bar 220 mm.
doi:10.1371/journal.pone.0102409.g003
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extracellular portion of MUC1, these responses are indicative of
humoral immunity against underglycosylated, tumor-like MUC1,
as previously shown by us and others [26]. Furthermore, mice
with endometrial hyperplasia also have detectable levels of
MUC1-specific antibodies, suggesting that MUC1 humoral
immunogenicity is an early event, triggered by early precursors
(Fig. S3D).
Overall, these results demonstrate that MUC1KrasPten mice
represent the first immune competent, orthotopic, human MUC1-
expressing preclinical tumor model for epithelial cell- derived
oviduct and endometrial tumors. The tumors have well defined
(endometrioid) histology, and, as with ovarian tumors [26],
overexpress MUC1 and trigger detectable levels of spontaneous
MUC1-specific humoral responses, closely mirroring the immu-
nogenicity seen in the respective human diseases [32,33].
KrasPten- induced oviductal and uterine tumors differ in
their nuclear grade, survival and immune
microenvironment
Although all genital tract tumors were endometrioid, a detailed
analysis of the H&E histo-pathology revealed that only oviduct
tumors developed as poorly differentiated, high nuclear grade
tumors, in contrast to the uterine and ovarian tumors which
occurred primarily as low/intermediate grade tumors (Fig. 5A).
Furthermore, mice with oviduct tumors had the lowest median
survival (12 weeks), significantly shorter than mice with endome-
trial tumors (Fig. 5B, p = 0.001). Surprisingly, no significance was
reached when compared with mice bearing ovarian tumors (13
weeks median survival, Table S1). Thus, the ovarian and oviductal
tumors mirror the characteristics of the human ovarian [1] and
fallopian tube cancers and share a similarly low survival, in spite of
the high nuclear grade observed only in the latter.
Figure 4. Increased human MUC1 protein expression in Kras- and Pten- driven genital tract tumors of MUC1KrasPten triple
transgenic mice triggers humoral immunity. (A) MUC1 immunohistochemistry staining of tumors occurring in the ovary (upper panel), oviduct
(middle panel) or endometrium (lower panel). An antibody specific to the human MUC1 extracellular domain (clone HMPV, mouse IgG1) was used at
1:100. Polarized MUC1 expression throughout the genital tract of healthy female mice at baseline is shown in Fig. S2. Mouse tumor MUC1 mimics
human tumor expression (shown in Fig. S5). Representative immunohistochemical images shown. Scale bar 250 mm. (B) ELISA measurement of
human MUC1 peptide-specific IgG antibodies in sera from MUC1KrasPten mice with tumors (n = 5 ovarian, n = 4 oviductal and n=4 uterine). Upper
panel: presence of antibodies at two different dilutions, using sing as target peptide a 100mer peptide comprising fie 20-aminoacid long peptide
from the MUC1 extracellular domain of MUC1. Background levels were detected using sera from KrasPten mice with MUC1 negative tumors (i.e. wild -
type for MUC1). Vehicle only was also included as an additional negative control. The assay was run in duplicate and values were plotted as means
with standard deviations. Lower panel: box and whisker diagrams (min, Q1, median, Q3, max) of readings at 1:20 dilution. Antibody levels are
significantly higher (compared to control readings) in the ovarian and oviduct tumor group (one way ANOVA p,0.05; *two tail t test; p,0.05).
Uterine tumors, p = 0.052.
doi:10.1371/journal.pone.0102409.g004
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To explore the relationship between survival, the observed
phenotype of oviduct tumors and the immune status of the host,
we phenotyped the splenic T cells via multicolor flow cytometry
and analyzed the percentages of all CD8 and CD4 T lymphocytes,
and of Foxp3 + (Treg) subset. The ratio of suppressors (Tregs) to
effectors (CD8 T lymphocytes) has been shown to correlate
inversely with survival of patients with ovarian [34] or other types
of tumors [35–37]. In line with these reports, we observed an
increased Foxp3 + T cell accumulation in the spleen of oviduct
tumor- bearing mice and a higher ratio of Treg/CD8 in these
mice compared to mice with uterine tumors (Fig. 5C, p,0.01). No
differences were noted between mice with ovarian and oviduct
tumors, suggesting that both anatomical locations are similar in
inducing an immune suppressive phenotype in the host, despite
the high nuclear grade observed only in the latter.
Discussion
Studies on targeted therapies, including immune-based ap-
proaches, require the development of adequate preclinical models
that best reflect the pathogenic changes seen in the human disease.
In this study, we generated two novel human MUC1- expressing
mouse models of oviductal and endometrial cancers respectively,
based on simultaneous KrasG12D activation and Pten deletion
mutations [21,26]. Using triple transgenic MUC1KrasPten mice
[26] we show for the first time that concomitant activation of
oncogenic Kras and deletion of Pten tumor suppressor throughout
the female mouse genital tract consistently triggers MUC1 positive
epithelial tumors with endometrioid histology. We previously
showed that MUC1 distribution throughout the genital tract of
MUC1KrasPten healthy mice is similar to the one seen in women
[26]. Here, we demonstrate that progression to genital cancers
triggers loss of polarized distribution and significant increase in
Figure 5. Kras- and Pten- induced tumors differ in nuclear grade and survival based on the anatomical site of mutation activation.
(A) Nuclear grade of primary tumor tissues of the ovary, oviduct and the uterus. Representative H&E images are shown. Scale bars: Main 220 mm,
Inset 2100 mm. (B) Kaplan Meyer curve shows that mice with uterine tumors survive significantly more than those with ovarian tumors (* p = 0.0015)
or those with ductal tumors (# p= 0.0016). Individual group comparison after post ANOVA Bonferroni correction (p,0.016). The numbers of mice in
each tumor group and median survival time for each tumor type are listed Table S1. Mice with premalignant lesions in the uterine tumor category
were excluded from analyses. (C) Splenic Treg/CD8 T cell ratios in mice with ovarian, oviduct or uterine tumors (n = 5 mice/group), represented as box
and whisker diagrams (min, Q1, median, Q3, max). CD4 and CD8 T lymphocytes were gated under the CD3 population. Foxp3 cells were gated under
the CD4 population. One way ANOVA for comparison of all means (p,0.03) and two tail t tests between any two groups show significant differences
between the ratios in uterine tumors and any of the other two tumor types, ovarian and oviduct (p,0.02 and p,0.01, respectively).
doi:10.1371/journal.pone.0102409.g005
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MUC1 protein expression. Furthermore, these changes trigger
humoral immune responses, most likely due to the release of
MUC1 from tumor cell surface followed by expansion of MUC1-
specific B cells in tumor draining lymph nodes [32,33,38]. Patients
with premalignant and malignant conditions of the genital tract
(mostly uterus and ovaries), as well as those affected with other
cancers [39] have increased MUC1 antibody titers, although the
intensity of these responses is variable. In line with these findings,
the triple transgenic MUC1KrasPten mice employed here, which
express human MUC1 as self, are able to undergo similar
pathogenic changes leading to local (ascites) and systemic (serum)
IgG antibody responses in ovarian, tubal and endometrial tumors.
This demonstrates the versatility of MUC1KrasPten mice in
modeling, with high fidelity, immunobiology of MUC1 in
gynecologic cancers.
A second major finding of our studies stems from the fact that
although the same genetic changes were turned on, at a similar
rate, throughout the genital tract epithelium (in the ovaries,
oviduct, endometrium), the tumor microenvironment seems to be
a key determinant of tumor grade and survival. Though
contiguous with the uterus and the ovary, and triggered via the
same KrasG12D and Ptendel mutations, the oviductal tumors show
a higher nuclear grade than those arising in the other organs. In
women, the high grade serous ovarian tumors are believed to arise
from fallopian tubes [4,5,15,40]. This hypothesis is further
validated by recent preclinical studies from Perets et al. who
reported a genetic model of de novo high grade serous carcinoma
that originates in fallopian tube epithelium and recapitulates the
biology of human invasive ovarian cancer [23]. Our results raise
the previously unexplored possibility that fallopian tubes may also
play a causative role in (albeit rare) cases of high grade
endometrioid or mixed endometrioid-serous ovarian carcinomas.
There are several examples in human carcinogenesis where the
anatomical site of initiating lesions dictates the cancer risk,
including the cervical epithelial transformation zone with HPV
[41], the esophageal-gastric junction and Barrett’s esophagus [42],
and the squamous cell metaplasia in lung cancer [43]. Here we
report that the intrinsic nature of the mucoso-epithelial biology of
the fallopian tube may promote a more aggressive phenotype, as
compared to the adjacent uterine mucosa when exposed to the
same carcinogenic influence. Our approach opens the door for
future studies focused on the identification of fallopian tube-
specific molecular pathways engaged in tumorigenesis and
development of new therapies that target these pathways. It also
provides further support to the rationale of scrutinizing the
fallopian tubes when searching for premalignant or early
precursors to high grade ovarian tumors, regardless of their
histology.
Preclinical mouse models to study oviductal cancer, the murine
equivalent of human fallopian tube carcinoma, are difficult to
develop. Recent studies from Kim et al utilized the anti-mu¨llerian
hormone receptor 2 (Amhr2) gene locus to deliver the Cre
recombinase and conditionally delete the Dicer and the Pten genes
in the mu¨llerian ducts to establish ductal cancer closely resembling
the human disease [15]. However, the Amhr2 gene is expressed
not only in oviductal cells but also in the uterine epithelium as well
as the ovarian granulosa cells [19], making this model non-
exclusive for primary oviductal tumors. Similarly, we acknowledge
the technical challenges posed by induction of oviduct tumors in
our MUC1KrasPten mice. Oviducts are minute tubes that provide
a space continuum between the uterine horns and the ovarian
bursa. To diminish the risk of leakiness, and to ensure that AdCre
injections remain anatomically confined to the oviducts, we
clipped the proximal and distal ends of the tubes, prior to AdCre
injections. The contrasting histomorphology (high grade in
oviducts versus low grade in ovaries and uterus) suggests that the
originating cells were indeed from the oviduct and that tumors
were not merely spreading from the contiguous genital tract areas
(ovary and uterus, respectively).
Unlike oviduct tumors, several preclinical models of uterine
carcinomatosis are currently available. Conditional deletions of
tumor suppressors such as Pten and p53 in the endometrium
trigger invasive endometrial adenocarcinomas [17,18]. In line with
these studies, our endometrial cancer mouse model did not show
100% penetrance. Mice with no visible tumors showed signs of
endometrial hyperplasia. The lesions were immunogenic and
triggered MUC1 antibodies, making this model attractive for
studies on MUC1 in uterine premalignancy.
The tumor microenvironment, composed of stroma and
immune cells, has recently received emphasis as a target in
treatment of ovarian cancer [44]. Our study reinforces its role in
the development of gynecological cancers. In addition, oviduct
tumor-bearing mice have Treg to CD8 ratios that are higher than
in mice with uterine tumors, yet not significantly different from
mice with ovarian tumors. This suggests that the oviducts promote
a more immune suppressive environment, perhaps similarly to
ovaries, via CXCL12 [45], although the exact mechanisms remain
to be identified.
Taken together, our studies establish two new, highly versatile
human MUC1- expressing mouse models of Kras- and Pten-
induced oviductal and endometrial cancers with endometrioid
histology, which closely mirror the pathology and immunogenicity
of human disease, and demonstrate the influence of the tumor
microenvironment on gynecological cancer development.
Supporting Information
Figure S1 Cre-mediated recombination at Kras and Pten loci,
in tumor-extracted DNA. PCR analysis of tumor-extracted DNA
shows concomitant activation of oncogenic KrasG12D mutation
(A) and deletion of Pten (B). Non-deleted Pten is shown in (C).
DNA from a healthy transgenic mouse was used as negative
controls in and B and positive control in C. DNA from an ovarian
cancer cell line was used as positive control in A and B. (A) Floxed
out, activated Kras shows up as upper band. (B) Floxed out Pten
shows as a single band; no band demonstrates absence of Cre-loxP
recombination. (C) Wild type Pten allele (arrow). (D) Activated
Kras levels expressed as percentage of total K-Ras in each sample.
(E, F) Pten deletion and wild type Pten allele, respectively; y axis,
signal intensity (arbitrary units). Signal in D-F were quantified
using Image Studio Lite (LI-COR). Ov T; ovarian tumor; Od T;
oviduct tumor; Endom; endometrial tumor.
(TIF)
Figure S2 AdLacZ administration into the oviduct or the uterus
was performed followed by staining for b-galactosidase expression.
4 micron sections of the specific tissue were cut and HE stained to
reveal the tissue histology. b-galactosidase expression in epithelia
of oviduct and the endometrium indicate successful delivery of the
adenovirus. A representative section is shown for each oviduct and
uterine anatomical site (Scale bars: low magnification 2100 mm,
high magnification 250 mm.
(TIF)
Figure S3 (A) Baseline endometrial histology of a healthy mouse.
(HE stain) (B) Premalignant lesions display cystic dilation and
endometrioid hyperplasia. (HE) stain) (C) The cyst lining as well as
the hyperplasic endometrial glands express human MUC1 (IHC
for MUC1 using anti-human MUC1 antibody, clone HMPV).
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Scale bar 2200 mm. (D) Dot plot of IG10-MUC1 cells incubated
with serum from uterine injected female mouse with endometrial
hyperplasia. Gated population represents percent tumor cells
stained by MUC1-specific antibodies present in the serum.
(TIF)
Figure S4 Histomorphology and MUC1 expression in the
normal mouse female genital tract. Left column: HE stain of a
female genital tract of a healthy, MKP mouse showing normal,
baseline histology of the ovary, oviduct and the uterus. Right
column: IHC stain for human MUC1 expression in the ovary,
oviduct and uterus of a healthy MKP female mouse. Scale bar 2
50 mm.
(TIF)
Figure S5 Histomorphology and MUC1 expression in human
gynecologic tumors. Left column: HE stains of human fallopian
tube carcinoma, endometrial carcinoma and endometrial hyper-
plasia. Right column: IHC stain for human MUC1 expression.
Representative images shown. Scale bar 250 mm.
(TIF)
Table S1 Median survival and number of mice in each tumor
group.
(DOCX)
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